Glenmark Pharmaceuticals Limited — Q3 FY24
Glenmark's Q3 FY24 consolidated revenue fell 16% YoY to INR 29,096 million, primarily due to a one-time India distribution restructuring that reduced channel inventory.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY24
Fluticasone MDI filing by Q4 FY24/Q1 FY25
Glenmark expects to file the fluticasone MDI (generic Flonase) in the US by end of FY24 or early FY25.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1